Hemolytic uremic syndrome (HUS) is a clinical triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. While this definition is clear, the syndrome is not a single disease but rather a spectrum of conditions with vastly different etiologies, treatments, and prognoses. The critical distinction lies between typical HUS, also known as Shiga toxin-producing E. coli HUS (STEC-HUS), and atypical HUS (aHUS). Although they share a common final pathway of endothelial damage and microvascular thrombosis, their underlying mechanisms, clinical triggers, and long-term outcomes diverge so significantly that they are best understood as two distinct disorders: one an acute, often self-limited infection, the other a chronic, life-threatening genetic disease of complement dysregulation.
Before the era of modern medicine, aHUS had a grim prognosis, with nearly 50% mortality or progression to end-stage renal disease (ESRD). typical vs atypical hemolytic uremic syndrome
Hemolytic uremic syndrome (HUS) is a complex and heterogeneous disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is a leading cause of acute kidney injury and end-stage renal disease in children and adults. HUS can be broadly classified into two categories: typical and atypical. Hemolytic uremic syndrome (HUS) is a clinical triad
In summary, while typical and atypical HUS share a common histopathological appearance and clinical triad, they are fundamentally distinct entities. Typical HUS is an acute, self-limited, toxin-mediated condition triggered by a gastrointestinal infection, primarily affecting children and carrying a good prognosis with supportive care. Atypical HUS is a chronic, genetic disease of complement dysregulation, affecting all ages, characterized by a high risk of recurrence and progression to ESRD. The distinction is not merely academic; it is the pivot upon which accurate diagnosis, appropriate treatment (supportive care versus complement inhibition), and accurate prognosis hinge. For the clinician, suspecting HUS is only the first step; the crucial second step is to determine which face of the syndrome is staring back. coli HUS (STEC-HUS), and atypical HUS (aHUS)